Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.
The anthrax protective antigen (PA) is the receptor-binding subunit common to lethal toxin (LT) and edema toxin (ET), which are responsible for the high mortality rates associated with inhalational Bacillus anthracis infection. Although recombinant PA (rPA) is likely to be an important constituent of any future anthrax vaccine, evaluation of the efficacies of the various candidate rPA vaccines is currently difficult, because the specific B-cell epitopes involved in toxin neutralization have not been completely defined. In this study, we describe the identification and characterization of two murine monoclonal immunoglobulin G1 antibodies (MAbs), 1-F1 and 2-B12, which recognize distinct linear neutralizing epitopes on domain 4 of PA. 1-F1 recognized a 12-mer peptide corresponding to residues 692 to 703; this epitope maps to a region of domain 4 known to interact with the anthrax toxin receptor CMG-2 and within a conformation-dependent epitope recognized by the well-characterized neutralizing MAb 14B7. As expected, 1-F1 blocked PA's ability to associate with CMG-2 in an in vitro solid-phase binding assay, and it protected murine macrophage cells from intoxication with LT. 2-B12 recognized a 12-mer peptide corresponding to residues 716 to 727, an epitope located immediately adjacent to the core 14B7 binding site and a stretch of amino acids not previously identified as a target of neutralizing antibodies. 2-B12 was as effective as 1-F1 in neutralizing LT in vitro, although it only partially inhibited PA binding to its receptor. Mice passively administered 1-F1 or 2-B12 were partially protected against a lethal challenge with LT. These results advance our fundamental understanding of the mechanisms by which antibodies neutralize anthrax toxin and may have future application in the evaluation of candidate rPA vaccines.
Kelly-Cirino
Cassandra D
CD
Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, 120 New Scotland Ave., Albany, NY 12208, USA.
Mantis
Nicholas J
NJ
D000595:Amino Acid Sequence; D000818:Animals; D000881:Anthrax / Q000517:prevention & control; D022122:Anthrax Vaccines / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000915:Antibody Affinity; D000942:Antigens, Bacterial / Q000737:chemistry / Q000276:immunology*; D001427:Bacterial Toxins / Q000737:chemistry / Q000276:immunology*; D018985:Epitopes, B-Lymphocyte / Q000276:immunology*; D005260:Female; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology
D022122:Anthrax Vaccines; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D018985:Epitopes, B-Lymphocyte; D011994:Recombinant Proteins; C030325:anthrax toxin
Proc Natl Acad Sci U S A. 1982 May;79(10):3162-6
6285339
Hum Vaccin. 2007 Sep-Oct;3(5):205-11
17881903
Nature. 1997 Feb 27;385(6619):833-8
9039918
Clin Infect Dis. 2008 Jan 1;46(1):129-36
18171228
J Biol Chem. 2003 Aug 15;278(33):30936-44
12771151
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11346-50
12177434
J Mol Biol. 2009 Apr 3;387(3):680-93
19361425
Infect Immun. 1988 Jul;56(7):1807-13
3384478
Nature. 2001 Nov 8;414(6860):225-9
11700562
Biochemistry. 1999 Aug 10;38(32):10432-41
10441138
Infect Immun. 2009 Jan;77(1):162-9
18981257
Nature. 2004 Aug 19;430(7002):905-8
15243628
Science. 1998 May 1;280(5364):734-7
9563949
Infect Immun. 1999 Apr;67(4):1860-5
10085028
J Infect Dis. 2006 Mar 1;193(5):625-33
16453257
J Immune Based Ther Vaccines. 2007 Oct 22;5:11
17953756
Infect Immun. 2001 Apr;69(4):2435-41
11254604
Clin Immunol. 2004 May;111(2):196-201
15137952
Vaccine. 2008 Oct 23;26(45):5684-8
18775462
FEMS Immunol Med Microbiol. 2006 Aug;47(3):436-43
16872381
Infect Immun. 2006 Jul;74(7):4149-56
16790789
Clin Vaccine Immunol. 2008 Jul;15(7):1115-23
18480236
Expert Rev Vaccines. 2008 Feb;7(1):55-74
18251694
Bioorg Med Chem. 2008 Feb 15;16(4):1903-13
18023190
J Biol Chem. 1991 Aug 15;266(23):15493-7
1651334
Annu Rev Cell Dev Biol. 2003;19:45-70
14570563
Biochem Pharmacol. 2003 Feb 1;65(3):309-14
12527323
Infect Immun. 2009 Mar;77(3):1197-207
19114543
Microbiology (Reading). 1996 Mar;142 ( Pt 3):707-715
8868446
Infect Immun. 2004 Jun;72(6):3276-83
15155630
J Biol Chem. 1992 Aug 15;267(23):16396-402
1644824
J Clin Invest. 2002 Jul;110(2):141-4
12122102
Infect Immun. 2004 Nov;72(11):6313-7
15501759
Biochemistry. 1998 Mar 17;37(11):3941-8
9521715
Nat Biotechnol. 2002 Jun;20(6):597-601
12042864
J Bacteriol. 2001 Mar;183(6):2111-6
11222612
Infect Immun. 2007 Nov;75(11):5443-52
17709410
Biochem Biophys Res Commun. 2006 Mar 24;341(4):1164-71
16460675
Infect Immun. 1999 Jun;67(6):2957-63
10338505
Proteins. 2008 Jan 1;70(1):218-30
17671962
Adv Drug Deliv Rev. 2005 Jun 17;57(9):1266-92
15935874
Infect Immun. 2001 May;69(5):2888-93
11292703
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6367-72
15079089
Biosens Bioelectron. 1998 Sep 15;13(6):653-63
9828359